How to assess and reduce Nitrosamine Contamination Risks in Peptide APIs

Recent years have seen drug recalls based on nitrosamine drug substance related impurities (NDSRIs), with medical agencies advising API manufacturers to implement risk assessment and mitigation strategies to meet safety and regulatory requirements. CDMOs often serve as a gatekeeper for potential nitrosamine contamination between starting materials and drug formulation. Join this webinar to learn how Bachem aims not only to satisfy the strictest regulatory requirements but ensures customers and patients alike can trust the quality of our peptides.The post How to assess and reduce Nitrosamine Contamination Risks in Peptide APIs appeared first on Bachem.Weiter zum vollständigen Artikel bei Bachem Holding AG Weiter zum vollständigen Artikel bei Bachem Holding AG